Is WUXI BIOLOGICS CAYMAN INC ORDINARY SHARE (OTCMKTS:WXIBF)’s Fuel Running High? Reports Show Less Sellers

The stock of WUXI BIOLOGICS CAYMAN INC ORDINARY SHARE (OTCMKTS:WXIBF) registered a decrease of 3.61% in short interest. WXIBF’s total short interest was 5.23M shares in July as published by FINRA. Its down 3.61% from 5.43M shares, reported previously. With 100 shares average volume, it will take short sellers 52339 days to cover their WXIBF’s short positions.

It closed at $9.2 lastly. It is up 0.00% since July 14, 2018 and is . It has underperformed by 4.43% the S&P500.

WuXi Biologics Inc., an investment holding company, provides integrated biologics outsourcing services worldwide. The company has market cap of $10.89 billion. The firm offers services for the discovery, development, and manufacture of biologics, such as monoclonal antibodies, recombinant therapeutic proteins, fusion proteins, vaccines, blood and blood components, allergenics, somatic cells, gene therapy, and tissues. It has a 191.67 P/E ratio. It serves pharmaceutical and biotechnology companies.

More notable recent WuXi Biologics (OTCMKTS:Cayman Inc) news were published by: Investorplace.com which released: “4 of the Best OTC Stocks to Buy for Future Growth – Investorplace.com” on June 05, 2019, also Seekingalpha.com with their article: “SoftBank Group Trades At A Considerable Discount To Its Portfolio – Rightfully So? – Seeking Alpha” published on December 10, 2018, Seekingalpha.com published: “Emerald Health Therapeutics Transformational Transaction – Seeking Alpha” on August 15, 2017. More interesting news about WuXi Biologics (OTCMKTS:Cayman Inc) were released by: Fool.com and their article: “Better Marijuana Stock: Aurora Cannabis vs. CannaRoyalty – Motley Fool” published on September 28, 2018 as well as Investorplace.com‘s news article titled: “Don’t Buy BIDU Stock Without Googling All of the Risk Factors – Investorplace.com” with publication date: December 11, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.